Use of ipidacrine in patients with peripheral nervous system diseases
P.R. Kamchatnov¹, F.K. Dzugaeva^2,3, A.V. Chugunov¹, A.Yu. Kazakov<sup>1

1</sup> Pirogov Russian National Research Medical University, Moscow
² North-Caucasian multidisciplinary medical center, Beslan
³ North Ossetian State Medical Academy, Vladikavkaz

Peripheral nervous system lesions are caused by a wide heterogeneous group of diseases. The most frequent clinical manifestations of them are peripheral paresis and pain syndromes. Adequate choice of drugs and non-drug treatment can achieve sufficient effectiveness in treatment of patients with peripheral nervous system diseases. One of directions of the treatment of such patients is use of acetylcholinesterase inhibitors (AChEI), and Axamon (ipidacrine) is a representative of this class of drugs. It has a stimulating effect on neuromuscular transmission and conduction of excitation through nerve fibers due to inhibition of AChEI activity and potassium channel blockade, which causes an elongation of the excitation period in a presynaptic fiber during a passage of nerve impulse and allows a large amount of acetylcholine to escape into a synaptic cleft. Due to inhibition of sodium channel activity, the use of drug provides a moderate analgesic effect. Possibilities of using the drug Axamon (ipidacrine) in mono- and polyneuropathies mainly with motor disorders — peripheral paresis, treatment of patients with facial nerve neuropathy are considered.

Key words: peripheral nervous system, peripheral paresis, nociceptive pain, neuropathic pain syndrome, treatment, ipidacrine, Axamon.
For citation: Kamchatnov P.R., Dzugaeva F.K., Chugunov A.V., Kazakov A.Yu. Use of ipidacrine in patients with peripheral nervous system diseases // RMJ. 2018. № 12(I). P. 44–48.